Carole Nuechterlein

Carole Nuechterlein has headed the Roche Venture Fund since 2001. She joined Roche from SangStat where she was General Counsel from 1998 to 2001. Prior to SangStat, Ms. Nuechterlein worked in the pharmaceutical/biotech industry as an attorney for ten years.

In addition to serving on CiVi Biopharma’s Board of Directors, Ms. Nuechterlein currently serves as a director at Aligos Therapeutics, Arch Oncology, Entrada Therapeutics, Maculogix, Millendo Therapeutics, Mission Therapeutics, Second Genome and Vivet Therapeutics. She was formerly a director at Allakos and AveXis.